Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS)
1 treatment and condition followed through the public trial records. Not medical advice. How a status is set
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS) for sarcoma, ewing | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |